Pharma & Bio
Technology
Lilly Buys Another BBB Platform… What Will Be the Impact on ABL Bio?
Competition in the blood-brain barrier (BBB) delivery platform sector is intensifying as Eli Lilly has secured the BBB shuttle platform of Swedish biotech firm BioArctic, following its acquisition of …
Lifestyle
Lemon Healthcare's Wild Debut, Vivozon's Clinical Boost [K-bio pulse]
On July 6, the pharmaceutical and biotechnology sector saw newly listed Lemon Healthcare experience a rollercoaster ride, surging early in the session before plummeting. PeopleBio rose on the back of …
Lifestyle
LEMON COMPANY LIMITED Rides a Roller Coaster on Its First Day of Trading… High Hopes for Vivzon’s Clinical Trials [Bio Spotlight]
On the 6th, the pharmaceutical and biotech sector saw a rollercoaster ride, with #LemonHealthcare—which went public that day—soaring before plummeting. PeopleBio, Inc.(304840)rose on the back of concr…
Technology
A Look at the Track Record of Underwriters for Rokit Healthcare’s U.S. IPO... 88% Traded Below the Offering Price
Rokit Healthcare is drawing significant attention amid expectations that its subsidiary, Rokit America, will list on the U.S. Nasdaq. On the 24th of last month, news that Rokit America had entered the…
Lifestyle
"Equipped with a Merck Partnership and Innovation Platform": What Are the Opportunities and Risks for Ingenia?
INGENIA Therapeutics (hereinafter “INGENIA”), considered a promising contender in the initial public offering (IPO) market for the second half of this year, has received approval for its preliminary l…
Technology
ILDONG PHARM Signs Term Sheet with Global Pharmaceutical Company for Padoprazan... Will It Shake Up the P-CAB Three-Way Race?
ILDONG PHARM(249420)has proven the value of Padoprazan on the global stage and has entered a race to accelerate its commercialization. This comes as partnership discussions in the U.S. are in full swi…
Lifestyle
Rigacem, Chosen by the Government... The K-Bio Investment Formula That 500 Billion Won Will Change
The government has, for the first time, injected large-scale policy funds into late-stage clinical trials for new drug development. This comes as the National Growth Fund has decided to make a direct …
Lifestyle
[K-Bio Pulse] Black Friday Hits Korean Biotech
South Korea’s pharmaceutical and biotech sector suffered broad-based losses on July 3 in what resembled a “Black Friday” for the industry. Stocks that had recently announced major positive development…
Lifestyle
Both Good and Bad News Were Shaken Off… K-Bio Faces 'Black Friday' [Bio Spotlight]
On the 3rd, pharmaceutical and biotech stocks plummeted across the board, creating a day reminiscent of “Black Friday.” Stocks that had been riding a wave of positive news—including LigaChem Bioscienc…
Business·Industry
Shin Tae-hyun, CEO of Inventera Inc.: “With Infinity, We’re Moving Beyond Precision Diagnostics to Take on Drug Delivery Therapies”
“Inventera Inc. is a company specializing in nanopharmaceuticals that develops diagnostic tools and therapeutics based on platform technologies that overcome the limitations of immune cell phagocytosi…